Davern Capital Partners, LP — 13F Holdings & Portfolio
CIK 2003147 · latest 13F-HR filed 2026-08-13
Davern Capital Partners, LP manages $586.5M in 13F-reported U.S. long-equity assets across 15 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are BNTX (11.97%), ROIV (11.66%), RPRX (11.05%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions, exited 5, added to 12, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
2ND FLOOR
NY, NY 10022
$586.5M
Long-equity book
15
Distinct positions
2026-06-30
Filed 2026-08-13
+3 / −5 / ↑12 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ROIVANT SCIENCES LTD$44.2M +182.7%
- BIONTECH SE$43.1M +159.0%
- ROYALTY PHARMA PLC$39.9M +159.8%
- IONIS PHARMACEUTICALS INC$34.3M +118.0%
- INSMED INC$29.8M +99.9%
New Positions
- ALNYLAM PHARMACEUTICALS INC$34.0M
- VERA THERAPEUTICS INC$21.4M
- AVALO THERAPEUTICS INC$8.7M
Exited Positions
- PFIZER INC$44.8M
- ARGENX SE$25.6M
- ELI LILLY & CO$25.1M
- ABIVAX SA$8.7M
- VIRIDIAN THERAPEUTICS INC$5.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | BIONTECH SE | BNTX | 09075V102 | $70.2M | 11.97% | 754,550 | SH |
| 2 | ROIVANT SCIENCES LTD | ROIV | G76279101 | $68.4M | 11.66% | 1,932,904 | SH |
| 3 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $64.8M | 11.05% | 1,155,809 | SH |
| 4 | IONIS PHARMACEUTICALS INC | IONS | 462222100 | $63.3M | 10.80% | 798,709 | SH |
| 5 | INSMED INC | INSM | 457669307 | $59.7M | 10.18% | 559,824 | SH |
| 6 | REGENERON PHARMACEUTICALS | REGN | 75886F107 | $57.8M | 9.85% | 92,640 | SH |
| 7 | LEGEND BIOTECH CORP | LEGN | 52490G102 | $34.4M | 5.87% | 1,191,522 | SH |
| 8 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $34.0M | 5.80% | 113,085 | SH |
| 9 | NATERA INC | NTRA | 632307104 | $32.3M | 5.51% | 118,975 | SH |
| 10 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $23.9M | 4.08% | 446,059 | SH |
| 11 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $23.2M | 3.95% | 858,753 | SH |
| 12 | VERA THERAPEUTICS INC | VERA | 92337R101 | $21.4M | 3.65% | 498,832 | SH |
| 13 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $13.9M | 2.37% | 824,679 | SH |
| 14 | PROCEPT BIOROBOTICS CORP | PRCT | 74276L105 | $10.5M | 1.79% | 464,920 | SH |
| 15 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $8.7M | 1.48% | 468,666 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $586.5M | 15 | 0000905148-26-003614 |
| 2026-03-31 | 2026-05-14 | $364.5M | 17 | 0000905148-26-002267 |
| 2025-12-31 | 2026-02-13 | $309.3M | 14 | 0000905148-26-000704 |